BHCG-VAC: Phase I data

Pooled data from 2 open-label, dose-escalation, U.S. Phase I trials in >70 patients showed that CDX-1307 produced 7 cases of stable disease for 2.2-6.5 months in patients with breast, colorectal or pa...